Novo Nordisk advances next-generation obesity drug to phase 3
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials. The decision follows feedback from regulatory authorities after the completion of earlier-stage studies for the weight-management treatment, according to the company.